What oral anticoagulants are approved in the United States for stroke prevention in patients with nonvalvular AF?
Three newer oral anticoagulants have been approved in the United States for stroke prevention in patients with nonvalvular AF: the direct thrombin inhibitor dabigatran (dosed at 150 mg twice daily in patients with creatinine clearance 30 mL/min) and the direct factor Xa inhibitors rivaroxaban (20 mg once daily for patients with creatinine clearance 50 mL/min) and apixaban (5 mg twice daily for patients with no more than 1 of the following characteristics: age 80 years, serum creatinine 1.5 mg/dL, or body weight 60 kg).